Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Cannabidiol (CBD) is scientifically validated as a treatment option for certain forms of epilepsy, particularly treatment-resistant childhood epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. Multiple well-designed, randomized controlled trials have demonstrated that CBD can significantly reduce the frequency of seizures in these patients when added to standard antiepileptic therapy. This has led to the approval of a purified, pharmaceutical-grade CBD product (Epidiolex) by the U.S. Food and Drug Administration (FDA) in 2018 specifically for these conditions.

The evidence supporting CBD’s efficacy comes from several landmark studies published in reputable medical journals. For example, a 2017 New England Journal of Medicine study showed that CBD reduced convulsive seizure frequency by 39% compared to 13% for placebo in Dravet syndrome. Similar results were seen for Lennox-Gastaut syndrome. Systematic reviews and meta-analyses also support these findings, though they note that efficacy is best established in specific syndromes and not generalized to all types of epilepsy.

The mechanism by which CBD reduces seizures is not fully understood but is thought to involve modulation of endocannabinoid signaling and other neurotransmitter systems. In summary, the use of CBD for certain forms of epilepsy is strongly supported by high-quality scientific evidence, resulting in regulatory approval for these indications.

More about Cannabidiol
More about Epilepsy

Other ingredients used for Epilepsy

Other health conditions supported by Cannabidiol

Products containing Cannabidiol